Kezar Deferred Long Term Liab vs Common Stock Analysis

KZR Stock

USD 0.69 0.01 1.47%

Kezar Life financial indicator trend analysis is infinitely more than just investigating Kezar Life Sciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kezar Life Sciences is a good investment. Please check the relationship between Kezar Life Deferred Long Term Liab and its Common Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kezar Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Deferred Long Term Liab vs Common Stock

Deferred Long Term Liab vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kezar Life Sciences Deferred Long Term Liab account and Common Stock. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kezar Life's Deferred Long Term Liab and Common Stock is -0.4. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Common Stock in the same time period over historical financial statements of Kezar Life Sciences, assuming nothing else is changed. The correlation between historical values of Kezar Life's Deferred Long Term Liab and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Kezar Life Sciences are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Deferred Long Term Liab i.e., Kezar Life's Deferred Long Term Liab and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Common Stock

Most indicators from Kezar Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kezar Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kezar Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

As of 06/03/2024, Selling General Administrative is likely to grow to about 27.9 M, though Issuance Of Capital Stock is likely to grow to (222.3 K).

Kezar Life fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.85	0.81	0.99	0.87	0.91	0.93	-0.39	-0.85	0.6	0.74	0.92	0.47	0.82	1.0	0.65	0.91	0.92	-0.41	0.91	0.52	0.91	-0.18	0.97	0.81	1.0
Other Current Liab	0.85		0.89	0.81	0.75	0.92	0.72	-0.36	-0.91	0.79	0.71	0.78	0.75	0.89	0.85	0.76	0.9	0.8	-0.28	0.92	0.67	0.89	-0.07	0.82	0.6	0.85
Total Current Liabilities	0.81	0.89		0.79	0.84	0.97	0.79	-0.16	-0.99	0.94	0.56	0.86	0.88	0.95	0.8	0.89	0.96	0.84	-0.38	0.98	0.9	0.96	-0.16	0.84	0.64	0.8
Total Stockholder Equity	0.99	0.81	0.79		0.9	0.91	0.94	-0.3	-0.83	0.58	0.65	0.92	0.44	0.77	0.99	0.61	0.9	0.9	-0.55	0.89	0.5	0.89	-0.34	0.96	0.78	0.99
Other Liab	0.87	0.75	0.84	0.9		0.9	0.88	-0.29	-0.81	0.65	0.6	0.87	0.57	0.8	0.87	0.58	0.88	0.74	-0.59	0.88	0.64	0.84	-0.4	0.85	0.87	0.87
Net Tangible Assets	0.91	0.92	0.97	0.91	0.9		0.87	-0.22	-0.97	0.85	0.62	0.9	0.76	0.92	0.91	0.82	0.99	0.89	-0.49	1.0	0.79	0.98	-0.27	0.91	0.7	0.91
Property Plant And Equipment Net	0.93	0.72	0.79	0.94	0.88	0.87		-0.16	-0.8	0.56	0.54	0.96	0.44	0.8	0.92	0.69	0.85	0.84	-0.5	0.86	0.52	0.87	-0.29	0.97	0.79	0.93
Net Debt	-0.39	-0.36	-0.16	-0.3	-0.29	-0.22	-0.16		0.18	-0.05	-0.89	-0.14	-0.01	-0.27	-0.41	0.08	-0.24	-0.25	-0.38	-0.22	0.06	-0.21	-0.47	-0.22	-0.57	-0.4
Retained Earnings	-0.85	-0.91	-0.99	-0.83	-0.81	-0.97	-0.8	0.18		-0.93	-0.59	-0.88	-0.85	-0.94	-0.85	-0.89	-0.98	-0.9	0.36	-0.99	-0.87	-0.98	0.13	-0.87	-0.63	-0.85
Accounts Payable	0.6	0.79	0.94	0.58	0.65	0.85	0.56	-0.05	-0.93		0.42	0.69	0.98	0.87	0.6	0.89	0.86	0.72	-0.25	0.87	0.98	0.85	-0.05	0.63	0.44	0.6
Cash	0.74	0.71	0.56	0.65	0.6	0.62	0.54	-0.89	-0.59	0.42		0.53	0.33	0.63	0.75	0.33	0.64	0.63	0.13	0.62	0.29	0.63	0.31	0.61	0.75	0.74
Non Current Assets Total	0.92	0.78	0.86	0.92	0.87	0.9	0.96	-0.14	-0.88	0.69	0.53		0.6	0.87	0.91	0.77	0.89	0.9	-0.46	0.9	0.65	0.9	-0.21	0.98	0.8	0.91
Non Currrent Assets Other	0.47	0.75	0.88	0.44	0.57	0.76	0.44	-0.01	-0.85	0.98	0.33	0.6		0.83	0.47	0.86	0.75	0.58	-0.17	0.78	0.96	0.74	0.01	0.52	0.37	0.47
Other Assets	0.82	0.89	0.95	0.77	0.8	0.92	0.8	-0.27	-0.94	0.87	0.63	0.87	0.83		0.81	0.91	0.91	0.79	-0.18	0.93	0.81	0.91	0.05	0.84	0.71	0.81
Cash And Short Term Investments	1.0	0.85	0.8	0.99	0.87	0.91	0.92	-0.41	-0.85	0.6	0.75	0.91	0.47	0.81		0.64	0.91	0.92	-0.41	0.9	0.51	0.91	-0.18	0.96	0.81	1.0
Net Receivables	0.65	0.76	0.89	0.61	0.58	0.82	0.69	0.08	-0.89	0.89	0.33	0.77	0.86	0.91	0.64		0.82	0.74	-0.16	0.85	0.86	0.85	0.04	0.74	0.41	0.64
Common Stock Total Equity	0.91	0.9	0.96	0.9	0.88	0.99	0.85	-0.24	-0.98	0.86	0.64	0.89	0.75	0.91	0.91	0.82		0.92	-0.45	0.99	0.8	0.99	-0.23	0.9	0.69	0.91
Common Stock Shares Outstanding	0.92	0.8	0.84	0.9	0.74	0.89	0.84	-0.25	-0.9	0.72	0.63	0.9	0.58	0.79	0.92	0.74	0.92		-0.35	0.9	0.64	0.93	-0.1	0.92	0.66	0.92
Non Current Liabilities Total	-0.41	-0.28	-0.38	-0.55	-0.59	-0.49	-0.5	-0.38	0.36	-0.25	0.13	-0.46	-0.17	-0.18	-0.41	-0.16	-0.45	-0.35		-0.44	-0.3	-0.41	0.96	-0.44	-0.24	-0.41
Capital Surpluse	0.91	0.92	0.98	0.89	0.88	1.0	0.86	-0.22	-0.99	0.87	0.62	0.9	0.78	0.93	0.9	0.85	0.99	0.9	-0.44		0.81	0.99	-0.22	0.9	0.68	0.9
Other Current Assets	0.52	0.67	0.9	0.5	0.64	0.79	0.52	0.06	-0.87	0.98	0.29	0.65	0.96	0.81	0.51	0.86	0.8	0.64	-0.3	0.81		0.79	-0.12	0.56	0.42	0.51
Other Stockholder Equity	0.91	0.89	0.96	0.89	0.84	0.98	0.87	-0.21	-0.98	0.85	0.63	0.9	0.74	0.91	0.91	0.85	0.99	0.93	-0.41	0.99	0.79		-0.18	0.92	0.66	0.91
Total Liab	-0.18	-0.07	-0.16	-0.34	-0.4	-0.27	-0.29	-0.47	0.13	-0.05	0.31	-0.21	0.01	0.05	-0.18	0.04	-0.23	-0.1	0.96	-0.22	-0.12	-0.18		-0.2	-0.03	-0.18
Property Plant And Equipment Gross	0.97	0.82	0.84	0.96	0.85	0.91	0.97	-0.22	-0.87	0.63	0.61	0.98	0.52	0.84	0.96	0.74	0.9	0.92	-0.44	0.9	0.56	0.92	-0.2		0.76	0.96
Preferred Stock Total Equity	0.81	0.6	0.64	0.78	0.87	0.7	0.79	-0.57	-0.63	0.44	0.75	0.8	0.37	0.71	0.81	0.41	0.69	0.66	-0.24	0.68	0.42	0.66	-0.03	0.76		0.81
Total Current Assets	1.0	0.85	0.8	0.99	0.87	0.91	0.93	-0.4	-0.85	0.6	0.74	0.91	0.47	0.81	1.0	0.64	0.91	0.92	-0.41	0.9	0.51	0.91	-0.18	0.96	0.81

Click cells to compare fundamentals

Kezar Life Account Relationship Matchups

Kezar Life fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	89.5M	151.8M	217.9M	299.6M	221.2M	159.6M
Other Current Liab	62K	21K	5.0M	6.0M	6.5M	6.8M
Total Current Liabilities	6.0M	6.4M	8.2M	11.0M	17.7M	18.6M
Total Stockholder Equity	78.0M	141.0M	196.9M	269.9M	187.6M	129.1M
Net Tangible Assets	78.0M	141.0M	196.9M	269.9M	310.4M	325.9M
Property Plant And Equipment Net	8.1M	6.7M	6.0M	13.2M	8.7M	6.8M
Net Debt	(8.6M)	(15.8M)	(48.8M)	(19.2M)	(16.6M)	(17.4M)
Retained Earnings	(84.3M)	(126.0M)	(180.7M)	(248.9M)	(350.8M)	(333.2M)
Accounts Payable	823K	2.4M	2.0M	2.5M	8.3M	8.7M
Cash	15.0M	21.2M	62.9M	40.5M	35.5M	35.7M
Non Current Assets Total	8.4M	7.0M	6.3M	13.8M	14.3M	7.9M
Cash And Short Term Investments	78.2M	140.4M	208.4M	276.6M	201.4M	147.6M
Net Receivables	642K	766K	70K	2.3M	2.6M	2.8M
Common Stock Shares Outstanding	19.1M	44.0M	52.8M	67.4M	72.6M	40.2M
Liabilities And Stockholders Equity	89.5M	151.8M	217.9M	299.6M	221.2M	159.6M
Non Current Liabilities Total	5.5M	4.4M	12.8M	18.7M	15.9M	16.7M
Capital Surpluse	162.5M	267.1M	377.8M	519.6M	597.6M	627.4M
Other Current Assets	1.0M	1.6M	729K	920K	3.3M	3.5M
Other Stockholder Equity	162.5M	267.1M	377.8M	519.6M	538.4M	565.3M
Total Liab	11.5M	10.9M	21.1M	29.7M	33.7M	22.1M
Property Plant And Equipment Gross	8.1M	6.7M	9.6M	17.8M	14.1M	8.7M
Total Current Assets	81.1M	144.8M	211.7M	285.7M	207.0M	151.6M
Accumulated Other Comprehensive Income	(196K)	(137K)	(291K)	(923K)	(130K)	(136.5K)
Property Plant Equipment	8.1M	3.4M	3.3M	3.4M	3.9M	4.0M
Net Invested Capital	78.0M	141.0M	206.5M	279.7M	197.6M	154.9M
Net Working Capital	75.1M	138.4M	203.4M	274.7M	189.2M	163.1M
Retained Earnings Total Equity	(84.3M)	(126.0M)	(180.7M)	(248.9M)	(224.0M)	(212.8M)
Short Term Investments	63.3M	119.2M	145.5M	236.1M	165.9M	149.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Kezar Life Sciences is a strong investment it is important to analyze Kezar Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Kezar Life's future performance. For an informed investment choice regarding Kezar Stock, refer to the following important reports:

How To Invest In Kezar

Details

Is Kezar Stock a good investment?

Details

What is Kezar Life's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kezar Life Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Kezar Life Sciences information on this page should be used as a complementary analysis to other Kezar Life's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Kezar Stock analysis

When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.

	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Kezar Life's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kezar Life. If investors know Kezar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kezar Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.39)

Revenue Per Share

0.096

Return On Assets

(0.27)

Return On Equity

(0.48)

The market value of Kezar Life Sciences is measured differently than its book value, which is the value of Kezar that is recorded on the company's balance sheet. Investors also form their own opinion of Kezar Life's value that differs from its market value or its book value, called intrinsic value, which is Kezar Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kezar Life's market value can be influenced by many factors that don't directly affect Kezar Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kezar Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kezar Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kezar Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kezar Deferred Long Term Liab vs Common Stock Analysis

Deferred Long Term Liab vs Common Stock

Deferred Long Term Liab vs Common Stock Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Common Stock

Kezar Life fundamental ratios Correlations

Kezar Life Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kezar Life fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Kezar Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Surpluse	+ 1.0	Net Tangible Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Capital Surpluse	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Total Current Liabilities
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.97	Net Tangible Assets
Other Assets	- 0.94	Retained Earnings